Type I interferons as radiosensitisers for XXXX .

@entity788 @entity686 @entity5 @entity19593 @entity2391
BACKGROUND: Radiotherapy is an established treatment for @entity5 . @entity788 however seems relatively insensitive to this form of therapy. METHODS: @entity788 cell lines MiaPaca-2 and Panc-1 were pre-treated with 3000 IU/ml @entity686 or 100 IU/ml @entity2391 followed by 0, 2, 4, or 6 Gray (Gy) irradiation. Colony forming assay was used to assess the effects on cellgrowth. To measure the surviving fraction at the clinically relevant dose of 2Gy ( @entity19593 ), cells were pre-treated with 1000-10.000 IU/ml @entity686 or 50-500 IU/ml @entity2391 followed by 2Gy irradiation. RESULTS: The plating efficiency was 49% for MiaPaca-2 and 22% for Panc-1. MiaPaca-2 was more radiosensitive than Panc-1 (surviving fraction of 0.28 versus 0.50 at 4 Gray). The @entity19593 of MiaPaca-2 was 0.77 while the @entity19593 of Panc-1 was 0.70. The @entity19593 significantly decreased after pretreatment with @entity686 1000 IU/ml (p<0.001) and @entity2391 100 IU/ml (p<0.001) in MiaPaca-2 and with @entity686 5000 IU/ml (p<0.001) and @entity2391 100 IU/ml (p<0.01) in Panc-1. The sensitising enhancement ratio (SER) for @entity686 3000 IU/ml was 2.15 in MiaPaca-2 and 1.90 in Panc-1. For @entity2391 100 IU/ml the SER was 1.72 for in MiaPaca-2 and 1.51 in Panc-1. CONCLUSIONS: Type I interferons have radiosensitising effects in @entity788 cell lines. This radiosensitising property might lead to an improved response to treatment in @entity788 . Interferon b is the most promising drug due to its effect in clinically obtainable doses.
